As of May 2026, PCOS has an official new name: polyendocrine metabolic ovarian syndrome, or PMOS. It's a change of just one letter in the acronym, but the thinking behind it reaches into how the condition is diagnosed, treated, researched, and understood.
Here's what the change actually means, and what it doesn't.
What PMOS Stands For
PMOS breaks down into three deliberate pieces:
Polyendocrine – The name now leads with hormones. This is a condition rooted in the endocrine system, involving multiple hormonal pathways rather than a single gland or organ.
Metabolic – This word captures the systemic side of the condition: insulin resistance, blood sugar regulation, cholesterol, and long-term cardiovascular risk. These features were largely invisible in the old name.
Ovarian – The ovaries are still in the picture. Abnormalities in follicle development and ovulation remain central features of the condition. The point isn't that the ovaries don't matter, it's that they aren't the whole story, and cysts don't define the syndrome.
"Syndrome" stays, because this is a cluster of related features rather than a single-cause disease.
Compare that to the old name. "Polycystic ovary syndrome" pointed almost entirely at the ovaries and at "cysts" that aren't actually cysts at all, they're immature follicles. For a condition that touches hormones, metabolism, cardiovascular health, and mental health, that framing was, at best, incomplete.
Why the Name Changed
The short version: the old name was inaccurate, and that inaccuracy had consequences.
The term "polycystic ovary syndrome" implied pathological ovarian cysts and obscured the broader endocrine and metabolic nature of the condition. Patients and clinicians alike reported that the name minimized the metabolic and systemic components—contributing to delayed diagnoses and fragmented care where symptoms got treated in isolation rather than as part of one whole-body condition.
This wasn't a rushed rebrand. The change followed more than a decade of debate and what researchers have called the largest and most robust medical renaming effort ever undertaken. The process was led by Professor Helena Teede at Monash University in Australia, in partnership with the International Androgen Excess and PCOS Society, patient-advocacy organizations like Verity (PCOS UK), and clinicians and patients across six continents. It gathered more than 22,000 survey responses and was formally published in The Lancet on May 12, 2026.
Crucially, the new name was chosen with patients, not just for them. In the consensus surveys, a large majority of patients and a solid majority of health professionals supported adopting a biologically accurate, symptom-based name over keeping the PCOS acronym. Lived-experience advocates were part of the process from the start—and several have described the previous name as a genuine misrepresentation of what they live with every day.
Why This Matters
A name might seem like semantics. Here's why this one isn't.
It reframes the condition for clinicians. When the name points at hormones and metabolism, it signals that care should look beyond fertility and menstrual cycles to include screening for things like blood sugar, cholesterol, and cardiovascular risk. For patients who've had metabolic symptoms waved off as unrelated, that reframing can mean more complete screening and earlier intervention.
It could accelerate research and funding. Under the name "PCOS," the condition read as a narrow gynecological issue. Framed as an endocrine and metabolic disorder, it now has a clearer stake for endocrinology, cardiology, metabolic medicine, and mental health research—not just reproductive medicine. The renaming team has explicitly named expanded research funding as a long-term goal, and more research ultimately means better screening tools and treatments.
It validates patient experience. For many people, the old name never matched the reality of living with the condition. Leading with hormones and recognizing the metabolic dimension puts the label closer to the lived experience—and that recognition matters.
This is a big condition, too. PMOS affects roughly 1 in 8 women—more than 170 million people worldwide—so the ripple effects of getting the framing right are enormous.
What It Means for You
If you've been diagnosed with PCOS, here's the reassuring part: the name changed, but the condition did not.
Your diagnosis is still valid. If you were diagnosed with PCOS, you now simply have PMOS. Nothing about your body, your diagnosis, or your risk profile is different than it was before.
No immediate action is required. You don't need to get re-tested or re-diagnosed because of the name change.
It's a good prompt for a fuller conversation. If you're not sure whether your care addresses the full picture—metabolic factors, cardiovascular risk, mental health—the new framing is a natural reason to raise those questions with your doctor.
It's also completely understandable if the switch feels disorienting. Many people have spent years learning about this condition, building community around it, and coming to terms with the "PCOS" label. Seeing it change can stir up a lot. That reaction is valid—and it doesn't undo any of the understanding you've built.
The Bottom Line
The move from PCOS to PMOS is one letter on paper and a meaningful shift in practice. It trades a name that pointed at "cysts that aren't cysts" for one that names what's really going on: a complex, whole-body hormonal and metabolic condition. The rollout is gradual—the international guideline used across 195 countries is expected to formally adopt the new terminology by 2028—so you'll likely see both names in use for a while yet.
But the direction is clear. And for a condition that's spent decades being underestimated by its own name, that's a change worth understanding.
This blog is for general educational purposes and isn't a substitute for personalized medical advice. If you have questions about your diagnosis or care, talk with your healthcare provider.
